SCHEMBL17801523

SCHEMBL17801523

O=c1cc2cc(F)c(NS(=O)(=O)c3ccc(Br)s3)cc2c[nH]1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.57
ATIC P31939 5/20 0.49
TP53 P04637 1/20 0.46
MAPT P10636 1/20 0.46
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
TDP1 Q9NUW8 2/20 0.42
NFKBIA P25963 2/20 0.42
RELA Q04206 2/20 0.42
POLB P06746 2/20 0.42
SLC40A1 Q9NP59 1/20 0.42
MAPK1 P28482 1/20 0.42
ALDH1A1 P00352 3/20 0.42
LMNA P02545 3/20 0.42
TSHR P16473 2/20 0.42
HTT P42858 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17801496 0.88 ATIC (0.51) THRBATICTP53MAPT
SCHEMBL17801458 0.82 ATIC (0.46) THRBATIC
SCHEMBL17801475 0.80 MEN1 (0.53) THRBTP53MAPTMEN1KMT2A
SCHEMBL17808588 0.78 ATIC (0.67) THRBATICTP53MAPTMEN1
SCHEMBL17801597 0.78 ATIC (0.50) THRBATIC
SCHEMBL17801538 0.75 ATIC (0.47) THRBATICTP53MAPTPOLB
SCHEMBL17801608 0.75 ATIC (0.46) THRBATIC
SCHEMBL17801533 0.72 ATIC (0.73) THRBATIC
SCHEMBL17801500 0.72 ATIC (0.54) ATIC
SCHEMBL17808590 0.66 ATIC (0.69) THRBATIC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3227279-A1 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS Eli Lilly and Company (US) 2017-10-11 EP disclosed
WO-2016089670-A1 1 -OXO-1,2-DIHYDROISOQUINOLIN-7-YL-(5-SUBSTITUTED-THIOPHEN-2-YL)-SULFONAMIDE COMPOUNDS, FORMULATIONS CONTAINING THOSE COMPOUNDS, AND THEIR USE AS AICARFT INHIBITORS IN THE TREATMENT OF CANCERS ELI LILLY AND COMPANY (US) 2016-06-09 WO disclosed